- Home
- IGMS vs BZFD Comparison
IGMS vs BZFD Comparison
Compare IGMS & BZFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- BZFD
- Stock Information
- Founded
- IGMS 1993
- BZFD 2006
- Country
- IGMS United States
- BZFD United States
- Employees
- IGMS N/A
- BZFD N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- BZFD Movies/Entertainment
- Sector
- IGMS Health Care
- BZFD Consumer Discretionary
- Exchange
- IGMS Nasdaq
- BZFD Nasdaq
- Market Cap
- IGMS 82.1M
- BZFD 77.5M
- IPO Year
- IGMS 2019
- BZFD N/A
- Fundamental
- Price
- IGMS $1.24
- BZFD $2.25
- Analyst Decision
- IGMS Hold
- BZFD
- Analyst Count
- IGMS 8
- BZFD 0
- Target Price
- IGMS $6.14
- BZFD N/A
- AVG Volume (30 Days)
- IGMS 198.4K
- BZFD 427.5K
- Earning Date
- IGMS 03-06-2025
- BZFD 03-13-2025
- Dividend Yield
- IGMS N/A
- BZFD N/A
- EPS Growth
- IGMS N/A
- BZFD N/A
- EPS
- IGMS N/A
- BZFD N/A
- Revenue
- IGMS $2,679,000.00
- BZFD $189,887,000.00
- Revenue This Year
- IGMS $134.71
- BZFD $89.62
- Revenue Next Year
- IGMS $74.27
- BZFD $4.50
- P/E Ratio
- IGMS N/A
- BZFD N/A
- Revenue Growth
- IGMS 25.77
- BZFD N/A
- 52 Week Low
- IGMS $1.15
- BZFD $1.26
- 52 Week High
- IGMS $22.50
- BZFD $5.68
- Technical
- Relative Strength Index (RSI)
- IGMS 37.38
- BZFD 51.52
- Support Level
- IGMS $1.17
- BZFD $2.12
- Resistance Level
- IGMS $1.31
- BZFD $2.48
- Average True Range (ATR)
- IGMS 0.09
- BZFD 0.14
- MACD
- IGMS 0.05
- BZFD 0.04
- Stochastic Oscillator
- IGMS 32.14
- BZFD 59.65
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About BZFD BuzzFeed Inc.
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.